Dexamethasone (Dextenza)
Small molecule
Evidence outlook
Approved: Ocular Inflammation and Pain, Allergic Conjunctivitis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Ocular inflammation and pain following ophthalmic surgery (DEXTENZA)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02034019 NCT02034019 · Ocular Inflammation and Pain This was a randomized, double-blind, placebo-controlled trial in 247 people with clinical primary endpoints (no inflammation in the eye at day 14 and no pain at day 8). The dexamethasone plug group did better on both counts, but the registry reports no statistical analysis, and the differences are not large enough to treat them as certainly significant without one. Registry: NCT02034019 | 3 | Absence of Cells in Anterior Chamber of the Study Eye (Day 14); Absence of Pain in Study Eye (Day 8) 2014-12 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 2 more trials
NCT02089113 NCT02089113 · Ocular Inflammation and Pain This randomized, double-masked, vehicle-controlled Phase 3 trial (Study 2 in the DEXTENZA label) placed a sustained-release dexamethasone intracanalicular insert (OTX-DP, Dextenza) or a vehicle insert after cataract surgery in 241 patients. It had two primary endpoints: absence of anterior chamber cells at Day 14 and absence of pain at Day 8. The pain primary was met, but the difference in absence of anterior chamber cells was not statistically significant (its 95% CI includes zero), so one primary was met and one was missed and the result is mixed. Source: the FDA-approved DEXTENZA label, which names this NCT. Registry: NCT02089113 | 3 | Number of Participants With an Absence of Anterior Chamber Inflammation (Day 14); Number of Participants With an Absence of Ocular Pain (Day 8) 2015-01 | Dextenza (dexamethasone 0.4 mg intracanalicular insert) vs vehicle insert, label Study 2: absence of anterior chamber cells at Day 14 63/161 (39%) vs 25/80 (31%), difference 8% (95% CI -5% to 21%); absence of pain at Day 8 124/161 (77%) vs 47/80 (59%), difference 18% (95% CI 6% to 31%) (DEXTENZA US label, section 14.1). | Partial signal | link ↗ |
NCT02736175 NCT02736175 · Ocular Inflammation and Pain This was a randomized, double-blind, placebo-controlled trial in 438 people with clinical primary endpoints (no inflammation in the eye at day 14 and no pain at day 8). The dexamethasone insert group did better on both, but the registry reports no statistical analysis, so whether the differences were significant cannot be confirmed from the record. Registry: NCT02736175 | 3 | Absence of Anterior Chamber Inflammation (Day 14); Absence of Ocular Pain (Day 8) 2016-05 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (43)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Glucocorticoid receptor drugs
albuterol / budesonide, Beclomethasone (QVAR), Betamethasone Dipropionate Emollient Spray, Budesonide (Entocort EC), budesonide (Ortikos) and 17 more. Compare all 23 Glucocorticoid receptor drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Allergic Conjunctivitis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dexamethasone (Dextenza): this drug | Approved | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Albuterol / Budesonide (Airsupra) | Approved(overall) | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Beclomethasone (QVAR) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Betamethasone Dipropionate Emollient Spray (Sernivo) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Entocort EC) | Approved(overall) | Small molecule | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Ortikos) | ApprovedUS marketing discontinued (overall) | — | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (targeted-Release) (TARPEYO / Nefecon) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide (Uceris Rectal Foam) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Budesonide MMX (Uceris) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ciclesonide (Alvesco) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Dexamethasone | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate (Arnuity Ellipta) | Approved(overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved(overall) | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved(overall) | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Foam (Lexette) | ApprovedUS marketing discontinued (overall) | Small molecule | Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Halobetasol Propionate Lotion (Bryhali) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone (Cortenema) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Hydrocortisone Acetate (Cortifoam) | Approved(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Approved(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Lodotra (Rayos) | US approval withdrawn(overall) | — | Glucocorticoid receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Freneslerbart / Mevonlerbart | Phase 3 | Monoclonal antibody | Fel d 1 (major cat allergen protein) | not yet graded | No reviewed efficacy summary in this indication | |
| Reproxalap | Phase 3 | Small molecule | Reactive aldehyde species (RASP) | Partial signal | Featured results are non-efficacy only in this race | |
| Dazucorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Miricorilant | Phase 2(overall) | Small molecule | Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Dexamethasone (Dextenza) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.